Why the study?
Diabetic cardiomyopathy is increasingly prevalent, but intervention targets remain unclear due to the lack of appropriate models and the complexity of risk factors.
Does empagliflozin alleviate cardiomyocyte injury and improve function in in vitro and mouse models of diabetic cardiomyopathy?
Does empagliflozin alleviate cardiomyocyte injury and improve function in in vitro and mouse models of diabetic cardiomyopathy?
Empagliflozin demonstrates direct protective effects against lipotoxic myocardial injury in human engineered heart tissue and mouse models of diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for empagliflozin in diabetic cardiomyopathy; prospective human trials needed before clinical adoption.
Diabetic cardiomyopathy (DbCM) is increasingly prevalent, but intervention targets remain unclear due to the lack of appropriate models and the complexity of risk factors. Here, this work establishes an in vitro assessment system for DbCM function using cardiomyocytes derived from human pluripotent stem cells and engineered heart tissue. This work finds high-fat status in complex diabetes risk factors majorly contributes most to cardiomyocyte death and contractile dysfunction. Notably, PA induced early electrophysiological abnormalities, and lately is associated with cardiac fibrosis, mitochondrial fission, and systolic and diastolic dysfunction at tissue level. Using this in vitro assessment system, this work finds that empagliflozin (EMPA), a first-line glucose-lowering drug, effectively alleviated early PA-induced cardiomyocyte injury. Treatment with EMPA enhanced abnormal diastolic and electrophysiological functions in the PA-hEHT model and significantly reduced endoplasmic reticulum stress, and apoptosis. Furthermore, these promising results are confirmed in a type 2 diabetes mellitus mouse model, reinforcing the potential of EMPA as a therapeutic option to alleviate cardiomyocyte injury under diabetic conditions. These findings suggest that this work has developed an engineered model of diabetic cardiomyopathy that mimics the various stages of lipotoxic myocardial injury and support the use of EMPA as a potential therapeutic option for diabetic or lipotoxic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: